Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD). The purpose of the open label extension is to assess the long‐term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.
Epistemonikos ID: 509fae2fea00063aea8365ce0cc58eb4d42a8ef0
First added on: May 21, 2024